MY165446A - Cdk8/cdk9 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer - Google Patents

Cdk8/cdk9 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer

Info

Publication number
MY165446A
MY165446A MYPI2014002269A MYPI2014002269A MY165446A MY 165446 A MY165446 A MY 165446A MY PI2014002269 A MYPI2014002269 A MY PI2014002269A MY PI2014002269 A MYPI2014002269 A MY PI2014002269A MY 165446 A MY165446 A MY 165446A
Authority
MY
Malaysia
Prior art keywords
methods
cdk8
cancer
cdki
relates
Prior art date
Application number
MYPI2014002269A
Other languages
English (en)
Inventor
B Roninson Igor
C Porter Donald
P Wentland Mark
Original Assignee
Senex Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senex Biotechnology Inc filed Critical Senex Biotechnology Inc
Publication of MY165446A publication Critical patent/MY165446A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
MYPI2014002269A 2012-02-02 2013-02-01 Cdk8/cdk9 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer MY165446A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261594023P 2012-02-02 2012-02-02
US201261673419P 2012-07-19 2012-07-19

Publications (1)

Publication Number Publication Date
MY165446A true MY165446A (en) 2018-03-22

Family

ID=47716178

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014002269A MY165446A (en) 2012-02-02 2013-02-01 Cdk8/cdk9 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer

Country Status (16)

Country Link
US (2) US9321737B2 (enExample)
EP (2) EP2809324B1 (enExample)
JP (1) JP6193268B2 (enExample)
KR (1) KR20150023223A (enExample)
CN (1) CN104363913B (enExample)
AU (1) AU2013214783B2 (enExample)
BR (1) BR112014019052A8 (enExample)
CL (1) CL2014002062A1 (enExample)
CO (1) CO7151516A2 (enExample)
EA (2) EA028595B1 (enExample)
GE (1) GEP201706688B (enExample)
MY (1) MY165446A (enExample)
PH (1) PH12014501862A1 (enExample)
SG (1) SG11201404596UA (enExample)
UA (1) UA117342C2 (enExample)
WO (1) WO2013116786A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102127025B1 (ko) 2012-07-27 2020-06-25 비오겐 엠에이 아이엔씨. S1p 조절제 및/또는 atx 조절제인 화합물들
MX2015002310A (es) * 2012-08-23 2015-06-05 Hoffmann La Roche Nuevas amidas de fenil-piridina/pirazina para el tratamiento de cancer.
US9636342B2 (en) 2012-11-01 2017-05-02 University Of South Carolina Method for treating prostate cancer
WO2014134169A1 (en) * 2013-02-26 2014-09-04 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
CN110183461A (zh) 2013-12-24 2019-08-30 哈佛学院院长等 皮质抑素类似物及其合成和用途
JP6529085B2 (ja) * 2014-04-18 2019-06-12 武田薬品工業株式会社 複素環化合物
EP3154952A4 (en) * 2014-06-10 2018-03-14 University of South Carolina Methods and compositions for treatment of her-positive cancers
EP3233086B1 (en) 2014-12-18 2023-02-15 University of South Carolina Suppression of neointimal formation following vascular surgery using cdk8 inhibitors
WO2016182904A1 (en) * 2015-05-08 2016-11-17 President And Fellows Of Harvard College Targeted selection of patients for treatment with cortistatin derivatives
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
EP3370720A1 (en) * 2015-11-03 2018-09-12 Lu License AB Compounds for treatment of hypoproliferative disorders
WO2017091836A1 (en) * 2015-11-25 2017-06-01 University Of South Carolina Enhancement of cytarabine activity by inhibiting cdk8/19
JP7198489B2 (ja) * 2016-03-23 2023-01-04 国立大学法人 岡山大学 リン酸化ｓａｒｍ１、抗体、ｓａｒｍ１リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、ｓａｒｍ１改変体及び使用
WO2018027082A1 (en) 2016-08-03 2018-02-08 The Broad Institute, Inc. Use of cdk8 inhibitors to treat diseases of inflammation and autoimmunity
ES3004107T3 (en) * 2017-01-30 2025-03-11 Univ Kyoto Novel compound, and method for producing regulatory t cells
WO2018151633A1 (ru) * 2017-02-20 2018-08-23 Закрытое Акционерное Общество "Биокад" Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов
US20220040179A1 (en) * 2017-02-23 2022-02-10 University Of South Carolina Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis
WO2018159805A1 (ja) 2017-03-03 2018-09-07 国立大学法人京都大学 膵前駆細胞の製造方法
JP7152784B2 (ja) * 2017-04-03 2022-10-13 京都薬品工業株式会社 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
RU2641001C1 (ru) * 2017-04-03 2018-01-15 Закрытое Акционерное Общество "Биокад" Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция
WO2019055977A1 (en) 2017-09-18 2019-03-21 Chan Zuckerberg Biohub, Inc. METHODS OF TREATING NEGATIVE TRIPLE BREAST CANCER
WO2019068613A1 (en) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS
RU2763347C2 (ru) * 2018-03-01 2021-12-28 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
US12281080B2 (en) 2018-08-21 2025-04-22 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
CN113677341B (zh) 2019-02-01 2024-07-05 南卡罗莱纳大学 双环吡啶组合物及其用于癌症治疗的方法
CN116391028A (zh) 2020-11-20 2023-07-04 千纸鹤治疗公司 促熟剂
WO2022172960A1 (ja) 2021-02-09 2022-08-18 オリヅルセラピューティクス株式会社 成熟化剤
CA3214794A1 (en) * 2021-03-25 2022-09-29 University Of South Carolina Cdk8/19 inhibitors for the treatment of cytokine storm
AU2022349176A1 (en) 2021-09-27 2024-04-11 Kyoto University Method for producing t cell
JPWO2023095802A1 (enExample) 2021-11-24 2023-06-01
TW202330911A (zh) 2021-11-24 2023-08-01 日商雷格細胞股份有限公司 人類誘導性控制性ｔ細胞及其製作方法
CN119256076A (zh) 2022-03-23 2025-01-03 国立大学法人京都大学 用于产生调节性t细胞的方法
KR20250006874A (ko) 2022-04-25 2025-01-13 오리즈루 세라퓨틱스 가부시키가이샤 Alk5 저해 활성과 cdk8/19 저해 활성을 갖는 성숙화제
AU2023307842A1 (en) 2022-07-14 2025-02-06 Orizuru Therapeutics, Inc. Fibrin gel sheet for cell transplantation
CN119948155A (zh) 2022-09-26 2025-05-06 雷格细胞股份有限公司 含有嵌合抗原受体（car）的诱导性调节性t细胞
JPWO2024071010A1 (enExample) 2022-09-26 2024-04-04
KR20250140618A (ko) 2023-02-08 2025-09-25 레그셀 가부시키가이샤 천포창을 치료 또는 예방하기 위한 의약 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
CA2306082A1 (en) * 1997-10-27 1999-05-06 Agouron Pharmaceuticals, Inc. Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
US20040180844A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
JP2006522794A (ja) * 2003-04-10 2006-10-05 ファイザー株式会社 Ｎｒ２ｂ受容体拮抗物質としての二環系化合物
EP2021019A4 (en) * 2006-05-15 2009-12-09 Senex Biotechnology Inc IDENTIFICATION OF CDKI PATH HAZARD
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2015506376A (ja) 2015-03-02
CN104363913A (zh) 2015-02-18
EP3431087A1 (en) 2019-01-23
EA032429B1 (ru) 2019-05-31
EA028595B1 (ru) 2017-12-29
AU2013214783A1 (en) 2014-08-28
AU2013214783B2 (en) 2017-07-06
BR112014019052A2 (enExample) 2017-06-20
US10993945B2 (en) 2021-05-04
US20140038958A1 (en) 2014-02-06
BR112014019052A8 (pt) 2017-07-11
JP6193268B2 (ja) 2017-09-06
PH12014501862A1 (en) 2014-11-24
CO7151516A2 (es) 2014-12-29
EA201491399A1 (ru) 2015-04-30
UA117342C2 (uk) 2018-07-25
WO2013116786A1 (en) 2013-08-08
SG11201404596UA (en) 2014-10-30
EP2809324A1 (en) 2014-12-10
KR20150023223A (ko) 2015-03-05
CL2014002062A1 (es) 2015-03-20
GEP201706688B (en) 2017-06-26
US20170071942A1 (en) 2017-03-16
EA201791284A1 (ru) 2017-10-31
EP2809324B1 (en) 2018-08-01
CN104363913B (zh) 2018-08-21
US9321737B2 (en) 2016-04-26

Similar Documents

Publication Publication Date Title
MY165446A (en) Cdk8/cdk9 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
UA115983C2 (uk) Інгібітори днк-пк
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
UA118261C2 (uk) Хімічні сполуки
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX363715B (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
MX378263B (es) Terapia de combinación para el tratamiento del cáncer.
PH12016502355A1 (en) Pharmaceutical composition
EA201591371A1 (ru) Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock
SG179418A1 (en) Inhibitors of the hedgehog pathway
MY184303A (en) Notch pathway signaling inhibitor compound
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
IN2015DN01151A (enExample)
MX351149B (es) Derivados biciclicos de pirazinona.
MX2011009033A (es) Inhibidores triciclicos de cinasa pirazolopiridina.
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
MX2015011614A (es) Derivados de pirrolidina, composiciones farmaceuticas que los contienen, y su uso en terapia.
MX2015012896A (es) Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
MX2017003466A (es) Inhibidores de histona desmetilasa.
GB201302704D0 (en) Therapeutic compounds
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
PH12015502744A1 (en) Bicyclic nitrogen-containing aromatic heterocyclic amide compound